演題番号 : O28-3
- 演者）曽田 均:1
- 伊瀬 洋史:1、白勢 大門:1,2、長谷川 浩之:2、末木 良太:2、進藤 邦明:2、小澤 俊総:1
The combination of Paclitaxel(PTX) and Ramucirumab(RAM) is an active regimen for metastatic gastric cancer as 2nd-line chemotherapy. We report efficacy and safety of this regimen retrospectively. A total 10 patients (average age=70.5) has been observed from Jan 2016 to Apr 2018. 6 of 10 cases had an operation for stomach. All cases have either or both peritoneum dissemination and lymph node metastases. The response rate(RR) for PTX+RAM was 10.0%. Disease control rate(DCR) was 70.0%. Median Overall survival(OS) was 5.4 months. Median Progression free survival(PFS) was 3.6 months, respectively. Major grade3/4 toxicities in the PTX+RAM included neutropenia(8 cases), white blood cell decreased(7 cases), anemia(4 cases), hypertension(1 case), dyspnea(1 case), abdominal distension(1 case), respectively. PTX+RAM regimen has enough safety. And it has not so highly RR, but has highly DCR as 2nd-line chemotherapy for metastatic gastric cancer.